Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What brings value to INVO? BioXcell. What brings Satellos value? Bertiliumumab indication for ophthalmology. Why does Bloom own major position in Satellos? It ain’t for unproven assets. Smart play. Gleeson is the little bitch that’s controlled by the Man. Cytovia is who controls the show of Naya. Who controls the show of Cytovia? Guess who. It sure ain’t little Teper. Choo Choo
Don’t fret about what’s already done and over. Just be patient. There is only a couple million shares available. Who owns those shares? Why is Bloom so interested in a company that is pumping bullshit assets? What asset isn’t it pumping? Is INVO a fund in plain site disguised as a company. Why would they? Is that possible? What do you think?
On November 20, 2023, the Company entered into a share exchange agreement with Cytovia Therapeutics Holdings, Inc. (“Cytovia”) for Cytovia’s acquisition of 1,200,000 shares of the Company’s newly designated Series B Preferred Stock in exchange for 163,637 shares of common stock of NAYA Biosciences Inc. (“NAYA”) held by Cytovia valued at $6,000,000. On November 20, 2023, the Company and Cytovia closed on the exchange of shares. Prior to the share exchange, Cytovia owned $50,000,000 in NAYA shares which it received as partial consideration for the acquisition by NAYA of two NK Engager bi-specific antibodies targeting, respectively, GPC3 for the treatment of Hepatocellular Carcinoma and CD38 for the treatment of Multiple Myeloma.
All is well people. Everything is acquired and all parts are moving well. Just waiting patiently for the boss to make the move. Someday they will strike the kettle when the kettle is hot and the whistle blows. Patience is the only thing you need now. Victory is ours board. It’s time to tighten the laces on our helmets.
RLK. I have known the whole time who you and all the other jackass aliases are. I played you for a fool. I can smell your shit from a mile away. I know exactly when Cytovia was founded. I know everything about everything when it comes to my investments. Enjoy the rest of the play. Have a great day! Just remember who kicked your ass left right and centre since 2015. So crazy how stupid some folk are. Stay you little Napoleon. Maybe stick around and learn from a real player. The player that wins it all. Enjoy the board I gave to you. You play with the bull you get the horns. Cheers
Great article on OakPoint Partners. Always on the hunt for IP. …… https://www.legaldive.com/news/remnant-assets-cash-generator-for-GCs-general-counsel-Oak-Point-Partners-Linn-Alwinn-intangibles/717252/
I smell something brewing…… rejection is breach…..claims can come…….shit is about to hit the fan
A U.S. debtor that is a licensee, or its trustee, is required to perform all of its obligations under the license agreement, unless and until the license agreement is rejected by order of the bankruptcy court.
A trademark license agreement, although it may not be treated as "intellectual property" under the Bankruptcy Code, is still an executory contract subject to assumption or rejection under the Bankruptcy Code and rejection provides the licensee with a damage claim (although no right to elect to continue using the IP under the license agreement under section 365(n)). Pursuant to the U.S. Supreme Court case discussed below, the rejection is deemed a breach, entitling the licensee to file a damage claim against the licensor-debtor, but is not deemed to be a termination of the agreement.
I hoped you asked permission dip shit,
Most courts have held that while a debtor-licensee can assume a non-exclusive license without consent of the licensor, the debtor-licensee cannot assign a non-exclusive license to a third party without consent. A notable minority of courts (particularly in California) have held that that the Bankruptcy Code prohibits a debtor-licensee’s assumption of a non-exclusive IP license without the consent of the licensor.
Well played Oakpoint. You no slouch. That’s one way to get in with us all. You’re a piece of shit. But great work…..
As a general rule, a debtor may exercise its own business judgment in determining whether to assume or reject an executory contract as part of its plan of reorganization. In addition, a debtor generally may assume an executory contract and then assign it to a third party as part of a sale of the debtor’s assets, even if there is an anti-assignment provision in the agreement. A debtor must cure pre-bankruptcy defaults before assuming any executory contract. If a debtor rejects an executory contract, then the rejection is deemed a pre-bankruptcy material breach of the contract and the counterparty will have a general unsecured claim for damages, which is a claim of low priority in the bankruptcy case.
I’m glad our IP shit is protected. Same goes for trademarks. Scary world out there. I will keep researching but new IP laws are a good thing. Canada, US and even Mexico are all changing. Good times for us folk.
https://resourcehub.bakermckenzie.com/en/resources/ip-licenses-and-insolvency-guide/jurisdiction/united-states/topics/what-does-the-applicable-law-provide#:~:text=When%20the%20bankrupt%20debtor%20is%20the%20licensor%2C%20the%20Bankruptcy%20Code,debtor%20licensees%20of%20intellectual%20property.
That fat pig already got his shares for free. He’s a Legacy shareholder and a ball breaker and a very bold funny guy. He loves poetry. It’s not me. He’s a better looking guy and much smarter one at that……….just joking. I have zero clue. I’m not smart enough to know who’s who in the zoo. I’m just crazy K.
Now we just need to get that IP back after this is sale is done. I hope Oakpoint wraps it in a bow. I wonder who the suitor will be. It better not be a four eyed, fat pig with lipstick.
Two birds one stone. I got the IP shit and the trademark shit. I got Immunis Inc. and its ability to use Immune Pharmaceuticals trademark symbol and I got the bankruptcy case where Immune Pharmaceuticals transferred IP to Oakpoint in Remnant sale. So awesome. A good night it is.
I just don’t stop learning.
On November 1, 2019, amendments to both the Bankruptcy and Insolvency Act (the “BIA”)[1] and the Companies’ Creditors Arrangement Act (the “CCAA”)[2] came into force that, amongst other things, address the rights of intellectual property (“IP”) licensees. Pursuant to the Budget Implementation Act, 2018, No. 2, these amendments protect IP licensee rights upon the insolvency of IP licensors, clarify acceptable business practices, and prevent the misuse of IP rights.[3] While the BIA and the CCAA do not provide a statutory definition of IP, Canadian IP rights are defined in IP statutes, as well as in other regulations and supporting jurisprudence.[4]
The new legislation creates a significant change for licensed IP rights in the insolvency context. Under the previous legislation, highly valuable IP assets of a company could encourage the company to take advantage of gaps in statutory protection that provide incentives to choose specific restructuring forums to exploit the value of the licensed IP.[5] Under the new provisions of the BIA and the CCAA,[6] at least in theory, the treatment of licensed IP rights should be substantively identical, regardless of the type of insolvency or bankruptcy proceeding that occurs.
HISTORICAL APPROACH
Prior to the recent amendments to the BIA and the CCAA, a 2009 amendment to the BIA and the CCAA limited a debtor’s right to disclaim IP license agreements if a notice of intention or a proposal was filed and the licensee continued to perform its obligations under the agreement in relation to the use of the IP. For receiverships and bankruptcies, IP license obligations were left to be determined by the common law. The outcome was that courts viewed IP licensing agreements within the receivership context as simply creating contractual agreements between parties, rather than establishing any form of property rights.[7]
The common law approach to licensed IP rights during a receivership was outlined by the Ontario Superior Court of Justice (Commercial List) in the case of Body Blue Inc.[8] In Body Blue Inc., title to certain IP was transferred by a receiver to a new owner pursuant to an approval and vesting order. The new owner moved for an order declaring that title to the IP was appropriately conveyed and that certain outstanding contractual or licensed rights ended. Another party, Herbal Care, claimed that they had an exclusive license for the manufacture and sale of the IP, and that the license was not affected by the approval and vesting order. The court noted that Herbal Care put forth no evidence to support any property interest in the IP and stated the following:[9]
However, even if established, a licence agreement only creates a contractual agreement as between the parties. Even if the grant to Herbal Care to market and sell were construed as a traditional licence, it is not the case that Herbal Care acquired a property interest in such a right.
The court determined that the new owner held the IP free and clear of the alleged licensed rights, and concluded that Herbal Care did not hold any property rights in such IP.
EFFECT OF AMENDMENTS
The new provisions of the BIA and CCAA alter the above historical process whereby receivers could disclaim IP licenses upon approval and vesting orders being granted for the transfer of IP ownership to third parties. In contrast to the previous common law method, the new provisions of the BIA and the CCAA provide more certainty to IP licensees by closing legislative gaps in insolvency or restructuring proceedings. In particular, the new provisions extend protection for IP licensees’ rights to all types of liquidation proceedings, including bankruptcies, receiverships, and asset sales, whereby there is an exception of contractual disclaimer rights granted to a debtor. The recent amendments attempt to create certainty for IP licensees, specifically as the license right will continue no matter how the licensed IP is handled, including if the IP is sold, disposed of, disclaimed, or resiliated, pursuant to any insolvency or restructuring proceedings under the BIA and the CCAA.[10]
However, the protection provided by the new provisions of the BIA and the CCAA does have its limits. While these new provisions extend the protection of IP license rights, licensees should be aware that the new provisions won’t necessarily guarantee protection for the value of the licensed IP. For instance, a licensee may hold a non-exclusive license granted by the owner of a trademark for use of such trademark. If the trademark owner becomes the subject of proceedings under the BIA or the CCAA, protection of the licensee’s rights to continue to use the trademark under the terms of the license is granted by the new legislation. However, if the ownership of the trademark is sold to a buyer who then uses that trademark in association with goods and/or services that are inferior to those it was originally associated with, the value of the trademark itself could diminish. Therefore, the licensee of the trademark may find that while it can still use the licensed trademark, the value of such trademark may suddenly be less than it was previously.
IP licensees should still exercise caution if they suspect the IP licensor is at risk of becoming insolvent, as the new legislative amendments will not be able to preserve the value of the licensed IP in all situations. The new provisions do, however, mark a step towards greater certainty for an IP licensee that their rights will subsist in a greater number of proceedings under the BIA and the CCAA.[11]
Good to know.
Preserving Intellectual Property Rights in Licenses: Changes to the Bankruptcy and Insolvency Act and the Companies’ Creditors Arrangement Act
Any ways folks. Just making a point. Marc is top notch in my books. Same goes for a few unknown bankers that I prefer not to name. Choo Choo
RELATED: Ex-AstraZeneca CMO Bohen lands at Olema Oncology as CEO
“I cannot think of a better leader to bring AZTherapies into its next evolutionary phase as we look ahead to the conclusion of our Phase 3 COGNITE trial in early Alzheimer’s disease, ramp up our ALZT-OP1 pre-commercial activities, and continue to advance our pipeline,” Elmaleh said in a statement Thursday. “Marc’s breadth of experience and successes across all aspects of global drug and corporate development give him a unique perspective that I believe will enable him to add significant value to the company. I look forward to working together to expand the outreach of our novel CNS platforms.”
Let’s see if I’m right about AZTherapies. Let’s just see…. https://www.fiercebiotech.com/biotech/ex-ipsen-boss-de-garidel-takes-helm-at-aztherapies
Peter has lots of connections…… https://www.northdata.com/Kuhn,+Peter,+Z%C3%BCrich/_p5605163999428608
I won’t be going down that rabbit hole. The only thing for sure is that it was VECTORLAB GMBH that Marc managed with Alex Something.
So they are selling AZTherapies as not Astra Zeneca. So I’m wrong about my assumption folk. Or am I right?????? Won’t know ever. These guys are slick.
Or shall I say……….AZTherapies,Inc. I want to make sure I say it correct. Don’t want to be cancelled out on my own board. I’m so funny. Hehehehehe
Guess what else Marc was a part of. Can you guess………..Survey says……Astra Zeneca.
Marc M. P. de Garidel is a French businessperson who founded Leem and who has been at the head of 11 different companies. He occupies the position of Non-Executive Chairman for Ipsen SA, Chairman at Ipsen Pharma SAS (a subsidiary of Ipsen SA), Chairman of G5, Chairman at Vectorlab GmbH and Chief Executive Officer & Director at AZTherapies, Inc. He is also on the board of European Federation of Pharmaceutical Industries & Assns, The Innovative Medicines Initiative and Société des Membres de la Légion d'Honneur and Professor at ESSEC Business School and Professor at ESCP Europe Campus Paris. In his past career he held the position of Non-Executive Chairman of PROMETHERA Biosciences SA, Chairman & Vice President at European Biopharmaceutical Enterprises, Finance Director for Eli Lilly & Co., Vice President-International at Amgen, Inc., Chairman for Suraypharm SAS, Chairman & Chief Executive Officer for Ipsen Pharma SAS, Chief Executive Officer & Director at Corvidia Therapeutics, Inc. and President at Leem. He received an undergraduate degree from Ecole Spéciale des Travaux Publics, a graduate degree from Thunderbird School of Global Management and an MBA from Harvard Business School.
Don’t forget people, VectorLab, which is a sub of Cytovia had about 300 million in yearly sales. You can thank Debere for reporting that shit. I did post it on Stocktwits years ago under one of my many aliases. Of course that only lasted so long thanks to Stocktwits and its corrupt ways. I’m cancelled there now. You can guess why. I ain’t no one’s friend and I report all that I find. Mostly all traders hate my guts. Rightly so. I open people’s eyes.
Found it guys. Found the name of VectorLab. He’s a freak of nature who is known as Marc M. P. de Garidel. I have high respect for this boy. He’s a machine and deserving of all. I believe he’s still working with IPSEN. Don’t know can’t remember. Don’t care. I do like IPSEN though. Good company.
The frozen shares I believe that are owned by Astra have added to the value. Now the question is, how to unfreeze?
Generally, an “estate freeze” involves the owner-manager exchanging their common shares of the privately held corporation for fixed-value preference shares that are equal to the fair market value of the corporate entity at that time. Through this exchange, the value of the privately held corporation becomes frozen in the preference shares held by the owner-manager. As the company grows in value, the additional value will be attributed to the new owners of the growth shares. The overall effect of an estate freeze is to pass the growth in value of the privately held corporation to either the children or other family members of the owner-manager or a family trust.
I also want to mention that no one can blame Teper here. He isn’t the mastermind. I could run laps around any of these CEOs and none of them are the guys behind this deal There a few guys that I could see this being planned by and it ain’t any of the puppets involved in these micro mergers. I would go after or connect the dots to the guys that don’t like the limelight. I think many know who I am talking about. At one time I thought that Teper etc was the one In control. Hell no. That was me being foolish and naive. I do believe that Astra plays a major role. The IPSEN / VectorLAB guy, I forget his name, sorry, was definitely a player here. Maybe even some of the Large Fund Managers could’ve made their mark. But in no way do I think Teper was involved. He’s just living off their good works.
What I can say is that ASTRA bought shares in 2021. They need to acquire the rest after bankruptcy completes. So nothing will be done until after the bankruptcy which we now know will have some more lawsuits coming and more confrontations. It’s coming people. Lawyers have agreed to not sue and Oakpoint has been given right of attorney to do whatever the fuck they agreed to. We don’t have that info. We aren’t privy to that shit. I wonder why?! Fucking crooked until the end. I wish there was some good actors, if that even exists in this corrupt world. Stay tuned.
So next termination in line is INVO / Naya Deal. Then comes ESHA deal with Cytovia. Then comes maybe Immunis or Satellos deal in Spring. Let’s hope for some Bankruptcy suits coming up as that’s the fund stuff. Micro mergers are meaningless as is the blank check deal.
I wonder how Astra deal plays with Immune acquisition. Technically Immune is already controlled by Astra. I wonder when second part of the acquisition comes. Maybe 2026. I would’ve figured there was a deadline to meat in a two part. I will need to research that shit out. Two part deals I thought had a deadline to realize. I don’t know much about anything with that stuff. Stay tuned. I will find out some way or another.
In my own opinion the great thing here is knowing that there is an end in sight and all is fully funded until 2027. I only say 2027 because Cytovia funding is being given at the end of 2024 and funding should mimic Isleworth funding timeline which lasted us a couple years. Now if that’s the case, then I don’t see anything really happening until after the funding is supposedly drained. Maybe there is another SPAC created or another company that will be created to make this go even further. My suspicions support that this will be the case. The ESHA funding is for trials that don’t need to be disclosed. Obviously they want to trickle out some news here, but they could also keep dead quiet other than reporting the fiscal periods that need to be reported for first year after combination. Then will come the next termination to occur in 2025. I wonder if there are any shareholders that are pissed or is it just me. It is what it is.
This is it people. I now understand completely this deal and everything I find only shows how these finance managers robbed shareholders and continue to do so with ESHA a blank check company. I can’t see many folk investing in that piece of shit. It’s all fund guys that have an inside scoop on the deal. They know what this will be terminated and dissolved to re-cap Cytovia. Most good folk wouldn’t be able to figure this shit out. Hell. I have problems myself sourcing info and I can only understand half of what I find. I was never this guy trying to solve the problems of the world. Now that’s what I do. Mind you I do it for fun. I ain’t know loser trying search for answers. This shit is genuinely fun for this dumb old fart. Love it.
All I see now is some lawsuits coming people. Maybe we see some stuff at the beginning of next year. At this stage we are still waiting for administration and that was given the ok signal for December 2024. Anything after is anyone’s guess. I can only assume that son of a bitch Trustee won’t be doing shit and that’s when Oakpoint comes in after. This is the way I see it. Eventually the truth is seen. Can’t hide forever. It’s funny people. I knew that this wasn’t close to being done. Still so many re-caps to do. Hell, the ESHA deal would run us out at least another 12 months from the combination which will be December at some point. Then you have the funding for Cellectis which runs us into 2026. Crazy but true. I look forward to the future cases in bankruptcy case. Thats the shit I enjoy. Fuck these mergers and the fund guys running them. They only wish they were me. I killed this deal. Killed it and I thwarted all those little idiots trying to get some. I can only assume they never planned on some farmer buying every damn share and then to top it offer, I never sold one damn share. Oops…. Sorry dick heads. I screwed up your plan. And don’t you worry, my hatred for you fucks will drive me to my victory in the end, I will also just get further educated which is even better. Knowledge is power and brings me lots of wealth and good feelings on my accomplishment. I have welcome all to not follow me as I have at least two more years of great investigational work that will only bring dismay. I glad;y walk on those burning coals and even better yet I gladly stop and stand on those coals enjoying the pain that is yet to come. You have messed with the wrong Fucker. I’m in until I win. Trust me. I will win as I do everyday. I could die today and know I have succeeded and have triumphed over all that is against me here. Hopefully you all feel the same. Stay crazy. Stay you. Never let anyone tell you differently. Hard work always pays off. Just try to make it look easy. Be well.
The future case that will be brought by Oakpoint makes perfect sense now. Something is coming. A default of some sort or whatever the fuck. I feel it in my britches. I now understand why the latest mutual release agreement was made between Trustee and Lowenstein and Sandler. Yup there is a no suing agreement. I get it now. I believe a group as pathetic as Lowenstein and Sandler would wipe the floor with Trustee if that person deviated or was intentionally slowing the process. Not now thanks to agreement. I see the light. They basically just agreed to let the Trustee do whatever the fuck is needed to extend the deal out for a couple years. This agreement will make sure there is no contention or disagreement in the future. It’s all becoming clearer. I thought originally that they were doing the mutual release agreement because they had settled and all was well. Nope that’s not the case. They were signing off on the plan to that would extend all out further for the next couple years. All makes sense now.
With Cellectis cash and cash equivalents of $149.0 million and deposit of $119.0 million as of June 30, 2024, the Company believes its cash and cash equivalents and deposits will be sufficient to fund its operations into 2026 and therefore for at least twelve months following the unaudited interim condensed consolidated financial statements' publication. Lots of time to short all businesses merging.
The full write off of asset works well with current plan to devalue the assets. Time is a wonderful tool. Must keep those assets worthless.
Cytovia is still on the hook, even though agreement has been terminated ( love that word terminated ). Awesome.
The convertible note was classified as a financial asset measured at fair value through profit or loss until June 30, 2023. The fact that Cytovia is in default substantially changes the cash flows associated with this asset, mainly as the convertible note is now only repayable in cash (and no longer subject to conversion into shares of Cytovia). We consider that the criteria for derecognition of this financial asset are met on June 30, 2023, and we therefore derecognized this asset to recognize a new asset, based on such new characteristics. On November 30, 2023, considering that the progress made in our negotiations with Cytovia was insufficient and in light of their failure to pay due and payable amounts under the note, we notified Cytovia the termination of the Cytovia Agreement. Under the terms of the termination letter, Cytovia is no longer authorized to use the licenses and rights granted under the Cytovia Agreement, but remains liable for the outstanding amount of the note and for which Cytovia is currently in default.
Considering new developments that occurred since June 30, 2023, including the termination of the Agreement, the end of our negotiation with Cytovia, Cytovia's resources and financing options and our ability to recover the receivable, we did not have reasonable expectations of recovery as of December 31, 2023. We therefore carried out a full write-off of the asset as of December 31, 2023.[img][/img]
Nothing will be completed for two years which I believe lines up with the funding.
I am looking forward to the lawsuits coming to get the shares. I never saw that coming. But I understand now.
So do not focus on any of these mergers that are controlled and there to recapitalize the deal that be.
Cellectis CEO is also just a paid puppet for Astra.
I mentioned before direct employment and I was wrong to say that. It is purely indirect employment that these people have a role in.
They are all indirectly paid fund managers. I never saw that in the beginning but it reigns true today.
One more thing. You must get past the fund managers intentions here. They are all bad actors. Daniel Teper, Shum, Gleeson, ESHA manager. All are employees of Astra and have always been employees of Astra, directly or indirectly. The goal is to fund, terminate and recapitalization. This is all this is. We will see more meaningless micro mergers like INVO. Watch and learn. It’s hard to get past but it is all true. Immunis as well is another company that will merge here. They are marked by the trademark symbol. You can’t do that without permission. Be well.
Cytovia will also be funded until 2nd half of 2026 once ESH Acquisition blank-check company makes its investment later 2024. This lines up nicely with Cellectis’s plans.
Still interested in when Oakpoint, who has now been given power of attorney for the sellers ( Immune ) after sale is completed shall begin lawsuit in defence of us creditors for the shares that will need to be distributed. Obviously they planned for a hold back of equity. I always thought along the lines that the US Trustee would be bringing on the lawsuit. I guess that’s not the case here.
Did anyone notice that it wasn’t just Remnant assets that were sold but also intellectual property and securities were also mentioned in the sale. That was pretty convenient eh. Also they have mentioned cash that would remain in judicial trust account for one year from the date of final sale of the remnant assets. So if that’s a sign, then this case will be ongoing for another year at least. At least in my head it will be. So once out of BK, there will be future litigation that will drag this out even further. Of course this is already understood because the management would want to divest shares at the same time as us general creditors. That’s a given I’m thinking. Look forward to future lawsuit to go after our claim. I’m trying to still wrap my head around who will be suing who when Trustee is looking after Administration and Final Decree. I assumed that it was a simple process where distribution would just be simply divided up between creditors. The only reason you would give your remnant buyer power of attorney is to make a claim on the creditors / debtors behalf. Stay tuned people. I’m still trying to figure things out, this stuff is way over my head. .
Very happy that Cellectis as of March 2024 have 5 million in restricted cash put aside in order to act as stand-by payment to pay off the outstanding loan in 2026. Thanks to Astra they have have been fully funded until 2026.
“Restricted cash is held aside by companies and is earmarked for a specific purpose. Restricted cash could be set aside for a particular purchase or to repay a loan or debt. Cash that has been deemed restricted cannot be used for other purposes.”
Don’t know if you noticed but even after remnant sale there could be some remaining assets. They explained that any cash, which may sit in judiciary account will be accounted for after a 1 year period that starts immediately after debtor case ends. It also states that intellectual property is also to be sold with remnant assets. So we have awhile yet to go. Stay you!
The IRS has ruled that the distributing corporation would have a 12-month period following the spinoff transaction to undertake a debt-for-equity exchange or otherwise distribute the remaining controlled corporation stock to its shareholders in a follow-on spinoff or split-off (in each case, tax-free under Sec. 355), with any remaining controlled corporation stock to be sold (generally, a taxable transaction) within five years of the spinoff (see, e.g., Letter Ruling 202151001 (Sept. 24, 2021), as supplemented by Letter Ruling 202231004 (May 12, 2022)).
Retention of stock: Finally, instead of a debt-for-equity exchange, the distributing corporation could potentially retain controlled corporation stock and subsequently dispose of it (generally, a taxable transaction). In general, under Sec. 355(a)(1)(D), the distributing corporation must distribute (1) all of the controlled corporation stock or (2) an amount of controlled corporation stock constituting Sec. 368(c) control and establish to the IRS’s satisfaction that the retention is not pursuant to a tax-avoidance plan. Under prior private letter ruling guidelines (see Rev. Proc. 96-30, Appendix B), retention of controlled corporation stock requires that (1) there be a separate business purpose for the retention (see, e.g., Rev. Rul. 75-321 (retention of controlled corporation stock to serve as collateral for distributing corporation debt)); (2) there generally be no overlap between officers and directors of the distributing and controlled corporations; (3) the distributing corporation dispose of the retained controlled corporation stock within five years after the spinoff transaction; and (4) the distributing corporation votes the retained controlled corporation stock in proportion to votes made by other controlled corporation shareholders.
It appears that Congress and the IRS are concerned that a retention could allow the distributing corporation to exercise control over the controlled corporation following the spinoff, which could be inconsistent with the general separation required under Sec. 355. Given the language of Sec. 355(a)(1)(D) (i.e., to establish to the IRS’s satisfaction that the retention does not involve tax avoidance), it may be prudent to seek a private letter ruling for any retention of controlled corporation stock.